

**BIOCON GROUP**

**FACT SHEET**

**December - 2017**

**BIOCON LIMITED (CONSOLIDATED)**  
**BALANCE SHEET**

(Rs Million)

	December 31, 2017	March 31, 2017
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	34,982	35,529
(b) Capital work-in-progress	7,114	5,327
(c) Investment property	7	8
(d) Goodwill	264	264
(e) Other intangible assets	426	458
(f) Intangible assets under development	4,227	3,065
(g) Investments in associates and a joint venture	584	422
(h) Financial assets		
Investments	-	1,458
Derivative assets	1,424	1,092
Other financial assets	241	197
(i) Income tax asset, net	1,154	895
(j) Deferred tax asset, net	1,888	1,975
(k) Other non-current assets	3,608	2,775
	<b>55,919</b>	<b>53,465</b>
<b>Current assets</b>		
(a) Inventories	7,355	6,353
(b) Financial assets		
Investments	12,339	10,650
Trade receivables	10,146	8,832
Cash and cash equivalents	3,619	7,102
Other bank balances	2,051	3,341
Derivative assets	1,270	1,059
Other financial assets	1,969	1,551
(c) Other current assets	1,599	1,589
	<b>40,348</b>	<b>40,477</b>
<b>TOTAL</b>	<b>96,267</b>	<b>93,942</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Share capital	3,000	1,000
(b) Other equity	47,632	47,377
<b>Equity attributable to equity holders of the Company</b>	<b>50,632</b>	<b>48,377</b>
Non-controlling interest	4,517	3,761
	<b>55,149</b>	<b>52,138</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	19,149	21,082
Derivative liability	71	61
Other financial liabilities	1	2
(b) Provisions	409	360
(c) Other non-current liabilities	3,331	3,516
	<b>22,961</b>	<b>25,021</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	2,070	972
Trade payables	9,623	7,397
Derivative liability	17	63
Other financial liabilities	3,962	3,261
(b) Short-term provision	558	468
(c) Income tax liability, net	953	964
(d) Other current liabilities	974	3,658
	<b>18,157</b>	<b>16,783</b>
<b>TOTAL</b>	<b>96,267</b>	<b>93,942</b>

**BIOCON LIMITED (CONSOLIDATED)****PROFIT & LOSS STATEMENT**

(Rs. Million)

Particulars	9M FY 18	9M FY 17	Variance
<b>INCOME</b>			
Small molecules	10,822	12,457	-13%
Biologics	5,294	5,385	-2%
Branded formulations	4,624	4,179	11%
Research services	10,140	9,097	11%
Inter-segment	(1,278)	(1,213)	5%
<b>Revenue from operations</b>	<b>29,602</b>	<b>29,905</b>	<b>-1%</b>
Other income	1,387	1,267	9%
<b>TOTAL REVENUE</b>	<b>30,989</b>	<b>31,172</b>	<b>-1%</b>
<b>EXPENDITURE</b>			
Material & Power costs	13,023	12,279	6%
Staff costs	6,119	5,093	20%
Research & Development expenses*	1,650	2,010	-18%
Other expenses	2,849	2,731	4%
<b>Manufacturing, staff &amp; other expenses</b>	<b>23,641</b>	<b>22,113</b>	<b>7%</b>
<b>EBITDA</b>	<b>7,348</b>	<b>9,059</b>	<b>-19%</b>
Interest & Finance charges	446	210	112%
Depreciation & Amortisation	2,898	2,047	42%
Share of profit in JV	(162)	(108)	50%
<b>PBT</b>	<b>4,166</b>	<b>6,910</b>	<b>-40%</b>
Taxes	1,162	1,513	-23%
Taxes on exceptional item	-	-	-
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>3,004</b>	<b>5,397</b>	<b>-44%</b>
Minority interest	584	551	6%
<b>NET PROFIT FOR THE PERIOD</b>	<b>2,420</b>	<b>4,846</b>	<b>-50%</b>
<b>EPS Rs.</b>	<b>4.0</b>	<b>8.1</b>	
# Licensing Income	205	1,294	
* Gross Research & Development expenses	2,829	3,041	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Million)
Particulars	Q3 FY 18	Q3 FY 17	Variance IndAS
<b>INCOME</b>			
Small molecules	3,688	4,069	-9%
Biologics	1,898	2,224	-15%
Branded formulations	1,561	1,233	27%
Research services	3,877	3,322	17%
Inter-segment	(445)	(404)	10%
<b>Revenue from operations</b>	<b>10,579</b>	<b>10,444</b>	<b>1%</b>
Other income	339	474	-28%
<b>TOTAL REVENUE</b>	<b>10,918</b>	<b>10,918</b>	<b>0%</b>
<b>EXPENDITURE</b>			
Material & Power costs	4,695	4,073	15%
Staff costs	2,145	1,795	19%
Research & Development expenses*	529	846	-37%
Other expenses	993	969	2%
<b>Manufacturing, staff &amp; other expenses</b>	<b>8,362</b>	<b>7,683</b>	<b>9%</b>
<b>EBITDA</b>	<b>2,556</b>	<b>3,235</b>	<b>-21%</b>
Interest & Finance charges	147	88	67%
Depreciation & Amortisation	974	703	39%
Share of profit in JV	(62)	(8)	675%
<b>PBT</b>	<b>1,497</b>	<b>2,452</b>	<b>-39%</b>
Taxes	361	544	-34%
Taxes on exceptional item	-	-	-
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>1,136</b>	<b>1,908</b>	<b>-40%</b>
Minority interest	217	195	11%
<b>NET PROFIT FOR THE PERIOD</b>	<b>919</b>	<b>1,713</b>	<b>-46%</b>
<b>EPS Rs.</b>	<b>1.5</b>	<b>2.9</b>	
# Licensing Income	118	794	
* Gross Research & Development expenses	942	1,000	

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Million)
Particulars	Q3 FY 18	Q2 FY 18	Variance
<b>INCOME</b>			
Small molecules	3,688	3,505	5%
Biologics	1,898	1,557	22%
Branded formulations	1,561	1,759	-11%
Research services	3,877	3,352	16%
Inter-segment	(445)	(487)	-9%
<b>Revenue from operations #</b>	<b>10,579</b>	<b>9,686</b>	<b>9%</b>
Other income	339	508	-33%
<b>TOTAL REVENUE</b>	<b>10,918</b>	<b>10,194</b>	<b>7%</b>
<b>EXPENDITURE</b>			
Material & Power costs	4,695	4,229	11%
Staff costs	2,145	2,043	5%
Research & Development expenses*	529	539	-2%
Other expenses	993	1,052	-6%
<b>Manufacturing, staff &amp; other expenses</b>	<b>8,362</b>	<b>7,863</b>	<b>6%</b>
<b>EBITDA</b>	<b>2,556</b>	<b>2,331</b>	<b>10%</b>
Interest & Finance charges	147	138	7%
Depreciation & Amortisation	974	936	4%
Share of profit in JV	(62)	(59)	5%
<b>PBT</b>	<b>1,497</b>	<b>1,316</b>	<b>14%</b>
Taxes	361	425	-15%
Taxes on exceptional item	-	-	0%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>1,136</b>	<b>891</b>	<b>27%</b>
Minority interest	217	203	7%
<b>NET PROFIT FOR THE PERIOD</b>	<b>919</b>	<b>688</b>	<b>34%</b>
<b>EPS Rs.</b>	<b>1.5</b>	<b>1.1</b>	
<i># Licensing Income</i>	118	10	
<i>* Gross Research &amp; Development expenses</i>	942	931	